Heng Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Heng Liang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Anton Gisterå
Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
1 shared publication- Jeffrey V. Ravetch
Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, USA
1 shared publication - Johan Hartman
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
1 shared publication - Kajsa Westberg
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Solna Campus, Stockholm, Sweden
1 shared publication Lars Nitschke
Division of Genetics, Department of Biology, University of Erlangen, Erlangen, Germany
1 shared publicationLi Lei
Department of Cell and Molecular Biology, Karolinska Institutet, Solna Campus, Stockholm, Sweden
1 shared publication
Latest Publications
- Open Access
- 27 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7410
Cancer immunotherapy targeting murine myeloid cells requires endosomal pattern recognition
Immunotherapy is now an established and efficient treatment option for many cancer patients. However, a proportion of patients still experience poor outcomes due to treatment resistance. Thus, a clear understanding of key mechanisms of resistance is needed for the development of new treatments. Here, we employ mouse models to explore an immunotherapeutic approach based on anti-MARCO (αMARCO) and anti-PD-L1 (αPD-L1) antibody-mediated targeting of tumor-associated macrophages (TAM). We demonstrate that effective immunotherapy relies on a functional endosomal pattern recognition machinery. We determine that endosomal Toll-like receptors (TLR), specifically TLR9, precondition macrophages to respond to αMARCO treatment by regulating the transcription of inflammasome components. Absence of TLRs renders TAMs unresponsive to treatment while retaining an immunosuppressive phenotype. Thus, we uncover the intracellular TLR signalling as a feature of immunotherapy efficacy, required to sensitise TAMs to treatment, and indicate that TLR targeting could be exploited to improve immunotherapeutic outcomes.
- 27 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7410
Open AccessCancer immunotherapy targeting murine myeloid cells requires endosomal pattern recognition
Immunotherapy is now an established and efficient treatment option for many cancer patients. However, a proportion of patients still experience poor outcomes due to treatment resistance. Thus, a clear understanding of key mechanisms of resistance is needed for the development of new treatments. Here, we employ mouse models to explore an immunotherapeutic approach based on anti-MARCO (αMARCO) and anti-PD-L1 (αPD-L1) antibody-mediated targeting of tumor-associated macrophages (TAM). We demonstrate that effective immunotherapy relies on a functional endosomal pattern recognition machinery. We determine that endosomal Toll-like receptors (TLR), specifically TLR9, precondition macrophages to respond to αMARCO treatment by regulating the transcription of inflammasome components. Absence of TLRs renders TAMs unresponsive to treatment while retaining an immunosuppressive phenotype. Thus, we uncover the intracellular TLR signalling as a feature of immunotherapy efficacy, required to sensitise TAMs to treatment, and indicate that TLR targeting could be exploited to improve immunotherapeutic outcomes.